Advanced search
Publication Cover
Acta Oto-Laryngologica Volume 129, 2009 - Issue 7
Submit an article Journal homepage
103
Views
10
CrossRef citations to date
0
Altmetric
ONCOLOGY

MASPIN's prognostic role in patients with advanced head and neck carcinoma treated with primary chemotherapy (carboplatin plus vinorelbine) and radiotherapy: preliminary evidence

Gino Marioni Department of Medical and Surgical Specialties, Section of Otolaryngology, University of Padova, PadovaCorrespondence[email protected]
,
Haralabos Koussis Istituto Oncologico Veneto IRCCS, Padova
,
Elena Gaio UOA ORL, Cittadella Civil Hospital, Cittadella
,
Luciano Giacomelli Department of Medical/Diagnostic Sciences and Special Therapies, Section of Anatomic Pathology, University of Padova, Padova, Italy
,
Andy Bertolin Department of Medical and Surgical Specialties, Section of Otolaryngology, University of Padova, Padova
,
Emiliano D'Alessandro Department of Medical/Diagnostic Sciences and Special Therapies, Section of Anatomic Pathology, University of Padova, Padova, Italy
,
Annamaria Scola Istituto Oncologico Veneto IRCCS, Padova
,
Giancarlo Ottaviano Department of Medical and Surgical Specialties, Section of Otolaryngology, University of Padova, Padova
,
Cosimo de Filippis Department of Medical and Surgical Specialties, Section of Otolaryngology, University of Padova, Padova
,
Antonio Jirillo Istituto Oncologico Veneto IRCCS, Padova
,
Alberto Staffieri Department of Medical and Surgical Specialties, Section of Otolaryngology, University of Padova, Padova
&
Stella Blandamura Department of Medical/Diagnostic Sciences and Special Therapies, Section of Anatomic Pathology, University of Padova, Padova, Italy
 show all
Pages 786-792 | Received 25 Jun 2008, Published online: 23 Nov 2009

References

  • Erjala K, Raitanen M, Kulmala J, Grenman R. Concurrent use of vinorelbine and gefitinib induces supra-additive effect in head and neck squamous cell carcinoma cell lines. J Cancer Res Clin Oncol 2007; 133: 169–76
  • Koussis H, Scola A, Bergamo F, Tonello S, Basso U, Karahontzitis P, et al. Neoadjuvant carboplatin and vinorelbine followed by chemoradiotherapy in locally advanced head and neck or oesophageal squamous cell carcinoma: a phase II study in elderly >70 years) or poor performance status patients. Anticancer Res 2008; 28(2B)1383–8
  • Espinosa E, Zamora P, Millá A, Morales S, Molina R, Mira M, et al. A phase II trial of cisplatin and vinorelbine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Head Neck 2002; 24: 1054–9
  • Helbekkmo N, Sundstrøm SH, Aasebø U, Brunsvig PF, von Plessen C, Hjelde HH, et al. Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. Br J Cancer 2007; 97: 283–9
  • Gebbia V, Mantovani G, Farris A, Agostara B, Desogus A, Curreli L, et al. Vinorelbine, cisplatin and 5-fluorouracil as initial treatment for previously untreated, unresectable squamous cell carcinoma of the head and neck. Results of a phase II multicenter study. Cancer 1997; 79: 1394–400
  • Bailey CM, Khalkhali-Ellis Z, Seftor EA, Hendrix MJ. Biological functions of maspin. J Cell Physiol 2006; 209: 617–24
  • Khalkhali-Ellis Z. Maspin: the new frontier. Clin Cancer Res 2006; 12: 7279–83
  • Wang SE, Narasanna A, Whitell CW, Wu FY, Friedman DB, Arteaga CL. Convergence of p53 and transforming growth factor beta (TGFbeta) signaling on activating expression of the tumor suppressor gene maspin in mammary epithelial cells. J Biol Chem 2007; 282: 5661–9
  • National Cancer Institute. Reporting Guidelines, Common Toxicity Criteria V2.0 (CTC), [available at:, http://ctep.cancer.gov/reporting/CTC-3.html].
  • Marioni, G, Staffieri, C, Staffieri, A, de Filippis, C, Blandamura, S. MASPIN tumour-suppressing activity in head and neck squamous cell carcinoma. Emerging evidence and therapeutic perspectives. Acta Otolaryngol Jul, 2008; 10:1–5, (Epub ahead of print).
  • Xia W, Lau YK, Hu MC, Li L, Johnston DA, Sheng S, et al. High tumoral maspin expression is associated with improved survival of patients with oral squamous cell carcinoma. Oncogene 2000; 19: 2398–403
  • Yasumatsu R, Nakashima T, Hirakawa N, Kumamoto Y, Kuratomi Y, Tomita K, et al. Maspin expression in stage I and II oral tongue squamous cell carcinoma. Head Neck 2001; 23: 962–6
  • Marioni G, Gaio E, Giacomelli L, Bertolin A, D'Alessandro E, Stramaze R, et al. Maspin subcellular localization and expression in oral cavity squamous cell carcinoma. Eur Arch Otorhinolaryngol 2008; 265(Suppl. 1)S97–S104
  • Marioni G, Blandamura S, Giacomelli L, Calgaro N, Segato P, Le G, et al. Nuclear expression of maspin is associated with a lower recurrence rate and a longer disease free interval after surgery for squamous cell carcinoma of the larynx. Histopathology 2005; 46: 576–82
  • Marioni G, D'Alessandro E, Giacomelli L, de Filippis C, Calgaro N, Sari M, et al. Maspin nuclear localization is related to reduced density of tumour-associated microvessels in laryngeal carcinoma. Anticancer Res 2006; 26: 4927–32
  • Marioni G, Giacomelli L, D'Alessandro E, Marchese-Ragona R, Staffieri C, Ferraro SM, et al. Nuclear localization of maspin: is its impact on the prognosis in laryngeal carcinoma due to a pro-apoptotic effect?. Am J Otolaryngol 2008; 29: 156–62
  • Surowiak P, Materna V, Drag-Zalesinska M, Wojner A, Kaplenko I, Spaczynski M, et al. Maspin expression is characteristic for cisplatin-sensitive ovarian cancer cells and for ovarian cancer cases of longer survival rates. Int J Gynecol Pathol 2006; 25: 131–9
  • Gynecologic Oncology Group. Secord AA, Lee PS, Darcy KM, Havrilesky LJ, Grace LA, Marks JR, et al. Maspin expression in epithelial ovarian cancer and associations with poor prognosis: A Gynecologic Oncology Group study. Gynecol Oncol 2006; 101: 390–7
  • Roncuzzi L, Marti G, Baiocchi D, Del Coco R, Cocchi S, Gasperi-Campani A. Effect of vinorelbine on cell growth and apoptosis induction in human osteosarcoma in vitro. Oncol Rep 2006; 15: 73–7
  • Lang DS, Droemann D, Schultz H, Branscheid D, Martin C, Ressmeyer AR, et al. A novel human ex vivo model for the analysis of molecular events during lung cancer chemotherapy. Respir Res 2007; 8: 43

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.